CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
(University of Texas M. D. Anderson Cancer Center) According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic Malignancies
The phase I trial is evaluating cobomarsen in cancers where the disease process appears to be correlated with an increase in miR-155 levels, including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 4, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA clears investigational new drug application for Calibr's 'switchable' CAR-T therapy
(Scripps Research Institute) Calibr, the drug discovery and development division of Scripps Research, today announced that the US Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's 'switchable' CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2020 Category: International Medicine & Public Health Source Type: news

AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL) Represents thir... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 31, 2020 Category: Pharmaceuticals Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

Single-cell sequencing of CLL therapy: Shared genetic program, patient-specific execution
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Researchers at the CeMM Research Center for Molecular Medicine and partners in Budapest have studied the response to targeted leukemia therapy in unprecedented detail, using single-cell sequencing and epigenetic analysis. The paper published in Nature Communications uncovers a precise molecular program in patients with chronic lymphocytic leukemia (CLL) who start treatment with ibrutinib. While this program was shared by all patients, the speed of its execution differed widely. These results will help develop personalized strategies for manag...
Source: EurekAlert! - Cancer - January 29, 2020 Category: Cancer & Oncology Source Type: news

Idelalisib May Induce More Favorable Outcomes in Clinical Trial Participants, Versus Medicare Beneficiaries
Medicare beneficiaries saw unfavorable results when compared to clinical trial participants being treated with idelalisib for their follicular lymphoma or chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Jennifer A. Woyach, MD, on the Alliance A041702 Trial in Chronic Lymphocytic Leukemia
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition. (Source: CancerNetwork)
Source: CancerNetwork - January 2, 2020 Category: Cancer & Oncology Authors: Jennifer A. Woyach, MD Source Type: news

CLL Highlights From ASH 2019 CLL Highlights From ASH 2019
Dr William Wierda of MD Anderson Cancer Center reviews key studies on chronic lymphocytic leukemia therapies presented at the 2019 American Society of Hematology (ASH) meeting in Orlando, Florida.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Revolutionary two-pronged attack that's beating 'incurable' blood cancer 
Professor Lelia Duley, 61, from Southwell in Nottinghamshire, is one of the patients involved in a drug combination trial to combat chronic lymphocytic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - December 28, 2019 Category: Consumer Health News Source Type: news

Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017
THURSDAY, Dec. 26, 2019 -- For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia& Lymphoma. Rudolf Weide, M.D., from the Praxis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 26, 2019 Category: Pharmaceuticals Source Type: news

IMBRUVICA ® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were m aintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA® · IMBRUVICA® plus ven e...
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Merck drops $2.7B on 26-year-old Burlington biotech
Drug giant Merck& Co. announced Monday that it will spend billions to buy a 26-year old biotech company that's struggled to bring a cancer drug to market.   Merck (NYSE: MRK) will spend approximately $2.7 billion to acquire Burlington-based ArQule Inc. (Nasdaq: ARQL). The biotech's drug that's furthest along in clinical trials is in the mid-stage tests against relapsed or refractory chronic lymphocytic leukemia. ArQule is expected to disclose more clinical data at an industry conference Monday. ArQule,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 9, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

Frontline Triplet Regimen Induces Undetectable MRD in the Bone Marrow of Patients with CLL
The triplet regimen consisting of acalabrutinib, venetoclax, and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta ®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options that achieve minimal residual disease (MRD)-negativity, in people with chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - December 8, 2019 Category: Pharmaceuticals Source Type: news

New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced updated data from two pivotal phase III Venclexta ®/Venclyxto® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta/Venclyxto combination treatments as chemotherapy-free, fixed-duration options that achieve minimal residual disease (MRD)-negativity, in people with chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - December 8, 2019 Category: Pharmaceuticals Source Type: news

Frontline Ibrutinib/Venetoclax Provides High Rates of Undetectable MRD in CLL
First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

Acalabrutinib Regimens Improve PFS in Treatment-Na ïve Patients with CLL
Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-na ïve patients with chronic lymphocytic leukemia (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients
(ECOG-ACRIN Cancer Research Group) The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the earlier trial findings (Shanafelt, New England Journal of Medicine, August 2019). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2019 Category: International Medicine & Public Health Source Type: news

Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Calquence Approved to Treat CLL, SLL
FRIDAY, Nov. 22, 2019 -- The U.S. Food and Drug Administration has granted supplemental approval to Calquence (acalabrutinib) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the agency announced... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 22, 2019 Category: General Medicine Source Type: news

Ohio State-developed drug receives FDA approval for treatment of CLL and SML
(Ohio State University Wexner Medical Center) On Nov. 21, 2019, the US Food and Drug Administration (FDA) approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma. This is the first full approval of the targeted drug therapy, which was developed and tested at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, in collaboration with the pharmaceutical partner, Acerta Pharma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news

AstraZeneca gets FDA ok for lymphocytic leukemia drug
AstraZeneca announced that the U.S. FDA has approved Calquence for adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 21, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Acalabrutinib to Treat CLL/SLL
As part of Project Orbis, The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 21, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2019 Category: Pharmaceuticals Source Type: news

Risk for Second Primary Malignancy Up in CLL Survivors
FRIDAY, Nov. 1, 2019 -- Survivors of chronic lymphocytic leukemia (CLL) have an increased risk for second primary malignancy (SPM), according to a study published online Sept. 30 in Blood Cancer Journal. Vivek Kumar, M.D., from Harvard Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news

PHARMAC funding venetoclax for chronic lymphocytic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2019 Category: Drugs & Pharmacology Source Type: news

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Hypertension & CV Adverse Events With Ibrutinib in'Real World'Hypertension & CV Adverse Events With Ibrutinib in'Real World '
Ibrutinib has changed the treatment landscape of chronic lymphocytic leukemia, but emerging real-world data suggest caution, owing to hypertension and other CV adverse events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Invasive Aspergillosis in Chronic Lymphocytic Leukemia: Therapy and Outcomes
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Chronic Lymphocytic Leukemia: 5 Things to Know Chronic Lymphocytic Leukemia: 5 Things to Know
The most common adult leukemia has seen a rush of new evidence in recent years. Here are some of the highlights.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 22, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Practical Dosing Considerations for Venetoclax
With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists.   (Source: CancerNetwork)
Source: CancerNetwork - September 20, 2019 Category: Cancer & Oncology Authors: Kelly Valla, PharmD, BCOP Source Type: news

' Possibility of Cure' for Some Patients With CLL'Possibility of Cure' for Some Patients With CLL
Ibrutinib is rapidly changing the treatment landscape in chronic lymphocytic leukemia (CLL), and experts are now talking about the possibility of a cure for some patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While  ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients. (Source: CancerNetwork)
Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Measurable Residual Disease Negativity at a High in Leukemia Trial
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax. (Source: CancerNetwork)
Source: CancerNetwork - August 20, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Drug Duo May Be a Weapon Against a Common Leukemia
The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival. (Source: WebMD Health)
Source: WebMD Health - August 1, 2019 Category: Consumer Health News Source Type: news

Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
THURSDAY, Aug. 1, 2019 -- For patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib-rituximab is more efficacious than chemoimmunotherapy, according to a study published in the Aug. 1 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2019 Category: Pharmaceuticals Source Type: news

Chronic Leukemia | Medscape Chronic Leukemia | Medscape
Chronic leukemias -- chronic myeloid leukemia and chronic lymphocytic leukemia -- occur mostly in adults and are extremely rare in children and young persons. Chronic lymphocytic leukemia has the highest familial incidence of the leukemias. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
TUESDAY, June 4, 2019 -- Venetoclax-obinutuzumab is associated with longer progression-free survival than chlorambucil-obinutuzumab among patients with untreated chronic lymphocytic leukemia (CLL) and coexisting conditions, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news

Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - June 4, 2019 Category: Pharmaceuticals Source Type: news

Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Roche today announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukaemia (CLL) showing that Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - June 4, 2019 Category: Pharmaceuticals Source Type: news

IMBRUVICA ® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2019 Category: Pharmaceuticals Source Type: news

Ibrutinib, Venetoclax Active in High - Risk, Seniors With CLL
Findings seen in phase 2 study of combo regimen for first - line treatment of chronic lymphocytic leukemia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 30, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL
THURSDAY, May 30, 2019 -- For high-risk and older patients with previously untreated chronic lymphocytic leukemia (CLL), the combination of ibrutinib and venetoclax is an active regimen, according to a study published in the May 30 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 30, 2019 Category: Pharmaceuticals Source Type: news

Ibrutinib and Venetoclax Combo'Impressive' in Front-Line CLL Ibrutinib and Venetoclax Combo'Impressive' in Front-Line CLL
The combination of ibrutinib and venetoclax has shown'impressive results'in the front-line treatment of chronic lymphocytic leukemia (CLL), and may not need to be continued indefinitely.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Patterns of chronic lymphocytic leukemia growth identified
(Dana-Farber Cancer Institute) In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study published in Nature. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2019 Category: International Medicine & Public Health Source Type: news

Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
(University of Texas M. D. Anderson Cancer Center) Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2019 Category: Cancer & Oncology Source Type: news